Mediterranean Diet and Postprandial Lipemia

Mediterranean vs. Low-Carbohydrate Diet : Which is the Best Dietary Approach for Treating Postprandial Lipid Abnormalities and Improving Glucose Control in Type 2 Diabetic Patients?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00789295

Enrollment

Unknown

Registered

2008-11-11

Start date

2004-03-31

Completion date

Unknown

Last updated

2008-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postprandial Lipemia, Type 2 Diabetes

Keywords

Mediterranean diet, Postprandial lipids, Postprandial glucose, High fibre diet, Low- CHO diet, High MUFA diet, Dietary approach

Brief summary

The aim of this intervention study was to evaluate in type 2 diabetic patients the effects on postprandial lipemia and other metabolic parameters (in both everyday life conditions and after a standard test meal) of two diets, one moderately rich in CHO, rich in fibre and with a low glycemic index (Mediterranean diet), and the other low in CHO and rich in MUFA (Low-CHO diet).Since adipose tissue, mainly through its lipolytic activities, is considered as having a pivotal role in the regulation of postprandial lipid metabolism, a further aim of our study was to clarify the role of adipose tissue in modulating the postprandial lipid response induced by the two dietary approaches by evaluating the activities of lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL).

Interventions

OTHERMediterranean diet and Low-Carbohydrates diet

The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * Stable metabolic control (HbA1c\<8.0%) on diet or diet alone or diet+metformin * BMI\<30 kg/m2 and body weight stable during the last six months. * Both sexes; only post-menopausal women. * Normal fasting lipid levels * No use of hypolipidemic drugs

Exclusion criteria

* Patient with renal (serum creatinine \>1.5 mg/dl) or hepatic (serum transaminases \>three times upper normal values) impairment. * Patients with history of cardiovascular disease. * Pre-menopausal women. * Any other acute or chronic degenerative disease. * Anemia (Hb\<12 g/dl). * Uncontrolled blood pressure. * Use of any drugs able to interfere with the study medications

Design outcomes

Primary

Measure	Time frame
Postprandial response triglyceride of chylomicrons and large VLDL	4 weeks

Secondary

Measure	Time frame
Blood glucose and insulin response to test meal	4 weeks
Lipolytic activities	4 weeks

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026